These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 35193644)
21. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme. Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406 [TBL] [Abstract][Full Text] [Related]
22. Correlation of MR-Based Metabolomics and Molecular Profiling in the Tumor Microenvironment of Temozolomide-Treated Orthotopic GL261 Glioblastoma in Mice. Zhao K; Calero-Pérez P; Bopp MHA; Möschl V; Pagenstecher A; Mulero-Acevedo M; Vázquez M; Barcia C; Arús C; Nimsky C; Rusch T; Bartsch JW; Candiota AP Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139457 [TBL] [Abstract][Full Text] [Related]
23. Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma. Lan F; Pan Q; Yu H; Yue X J Neurochem; 2015 Sep; 134(5):811-8. PubMed ID: 25991372 [TBL] [Abstract][Full Text] [Related]
24. Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response. Hombach-Klonisch S; Mehrpour M; Shojaei S; Harlos C; Pitz M; Hamai A; Siemianowicz K; Likus W; Wiechec E; Toyota BD; Hoshyar R; Seyfoori A; Sepehri Z; Ande SR; Khadem F; Akbari M; Gorman AM; Samali A; Klonisch T; Ghavami S Pharmacol Ther; 2018 Apr; 184():13-41. PubMed ID: 29080702 [TBL] [Abstract][Full Text] [Related]
25. Nek1-inhibitor and temozolomide-loaded microfibers as a co-therapy strategy for glioblastoma treatment. Reinhardt LS; Morás AM; Henn JG; Arantes PR; Ferro MB; Braganhol E; de Souza PO; de Oliveira Merib J; Borges GR; Dalanhol CS; de Barros Dias MCH; Nugent M; Moura DJ Int J Pharm; 2022 Apr; 617():121584. PubMed ID: 35202726 [TBL] [Abstract][Full Text] [Related]
26. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT. Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036 [TBL] [Abstract][Full Text] [Related]
28. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma. Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952 [TBL] [Abstract][Full Text] [Related]
29. Hsa_circ_0072309 enhances autophagy and TMZ sensitivity in glioblastoma. Yuan F; Zhang S; Sun Q; Ye L; Xu Y; Xu Z; Deng G; Zhang S; Liu B; Chen Q CNS Neurosci Ther; 2022 Jun; 28(6):897-912. PubMed ID: 35212145 [TBL] [Abstract][Full Text] [Related]
30. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway. Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060 [TBL] [Abstract][Full Text] [Related]
31. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance. Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522 [TBL] [Abstract][Full Text] [Related]
32. The HIF‑1α/miR‑224‑3p/ATG5 axis affects cell mobility and chemosensitivity by regulating hypoxia‑induced protective autophagy in glioblastoma and astrocytoma. Huang S; Qi P; Zhang T; Li F; He X Oncol Rep; 2019 Mar; 41(3):1759-1768. PubMed ID: 30569180 [TBL] [Abstract][Full Text] [Related]
33. Tumor-Associated Microglia/Macrophages as a Predictor for Survival in Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance Overcoming Strategy by Combination Therapy. Urbantat RM; Jelgersma C; Brandenburg S; Nieminen-Kelhä M; Kremenetskaia I; Zollfrank J; Mueller S; Rubarth K; Koch A; Vajkoczy P; Acker G Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681839 [TBL] [Abstract][Full Text] [Related]
34. Bone marrow response as a potential biomarker of outcomes in glioblastoma patients. Vaios EJ; Nahed BV; Muzikansky A; Fathi AT; Dietrich J J Neurosurg; 2017 Jul; 127(1):132-138. PubMed ID: 27739940 [TBL] [Abstract][Full Text] [Related]
35. The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment. Patties I; Kallendrusch S; Böhme L; Kendzia E; Oppermann H; Gaunitz F; Kortmann RD; Glasow A J Exp Clin Cancer Res; 2019 Oct; 38(1):420. PubMed ID: 31639020 [TBL] [Abstract][Full Text] [Related]
36. Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy. Golden EB; Cho HY; Jahanian A; Hofman FM; Louie SG; Schönthal AH; Chen TC Neurosurg Focus; 2014 Dec; 37(6):E12. PubMed ID: 25434381 [TBL] [Abstract][Full Text] [Related]
37. Lnc-TALC promotes O Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733 [TBL] [Abstract][Full Text] [Related]
38. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation. Liang H; Chen Z; Sun L Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274 [TBL] [Abstract][Full Text] [Related]